Czech national cancer screening programmes in 2010

Klinicka Onkologie

Volumn 23, Issue 5, 2010, Pages 343-353

  Majek O ^a   Danes J ^b   Zavoral, M ^b   Dvorak V ^c   Suchanek S ^b   Seifert, B ^b   Kozeny P ^d   Panova S ^e   Dušek, Ladislav ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Czech Gynecological and Obstetrical Society   (Czech Republic)

^d National Reference Centre   (Czech Republic)

^e Institute of Health Information and Statistics of the Czech Republic   (Czech Republic)

Author keywords

Cancer screening; Information system; Malignant neoplasms

Indexed keywords

ADENOMA; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; COLONOSCOPY; COLORECTAL CANCER; EUROPE; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; INFORMATION SYSTEM; MAMMOGRAPHY; PERFORMANCE MEASUREMENT SYSTEM; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CZECH REPUBLIC; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; UTERINE CERVICAL NEOPLASMS;

EID: 78149325259     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Council recommendation of 2 December 2003 on cancer screening (2003/878/EC). Official J Eur Union 2003, L 327/34:85-89.
2. Schopper D, de Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer 2009; 45(11): 1916-1923.
3. Olsen AH, Njor SH, Vejborg I et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ 2005; 330(7485): 220
4. Sarkeala T, Heinävaara S, Anttila A. Organised mammography screening reduces breast cancer mortality: a cohort study from Finland Int J Cancer 2008; 122(3): 614-619.
5. Gabe R, Tryggvadóttir L, Sigfússon BF et al. A case-control study to estimate the impact of the Icelandic population-based mammography screening program on breast cancer death. Acta Radiol 2007; 48(9): 948-955.
6. Paci E, Coviello E, Miccinesi G et al. Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. Eur J Cancer 2008; 44(6): 858-865.
7. Otto SJ, Fracheboud J, Looman CW et al Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003; 361(9367): 1411-1417.
8. Ascunce EN, Moreno-Iribas C, Barcos Urtiaga A et al. Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme. J Med Screen 2007, 14(1): 14-20.
9. SOSSEG. Reduction in breast cancer mortality from the organized service screening with mammography: 1. Further confirmation with extended data Cancer Epidemiol Biomarkers Prev 2006; 15(1): 45-51.
10. SOSSEG. Reduction in breast cancer mortality from the organised service screening with mammography: 2. Validation with alternative analytic methods Cancer Epidemiol Biomarkers Prev 2006; 15(1): 52-56.
11. Blanks RG, Moss SM, McGahan CE et al. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-1998: comparison of observed with predicted mortality BMJ 2000; 321(7262): 665-669.
12. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328(19): 1365-1371.
13. Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348(9040): 1472-1477.
14. Kronborg O, Fenger C, Olsen J et al Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348(9040): 1467-1471. (Pubitemid 26400241)
15. Kronborg O, Jørgensen OD, Fenger C et al. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004; 39(9): 846-851.
16. Hewitson P, Glasziou P, Watson E et al Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103(6): 1541-1549.
17. Mandel JS, Church TR, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343(22): 1603-1607.
18. Guittet L, Bouvier V, Marione N et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56(2): 210-214
19. Levi Z, Rozen P, Hazazi R et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007, 146(4): 244-255.
20. Zheng S, Chen K, Liu X et al Cluster randomization trial of sequence mass screening for colorectal cancer. Dis Colon Rectum 2003; 46(1): 51-58.
21. Baxter NN, Goldwasser MA, Paszat LF et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009; 150(1): 1-8.
22. Brenner H, Hoffmeister M, Arndt V et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study J Natl Cancer Inst 2010; 102(2): 89-95
23. Kahi CJ, Imperiale TF, Juliar BE et al. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009, 7(7) 770-775.
24. Winawer SJ, Zauber AG, Ho MN et al Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329(27): 1977-1981.
25. Ransohoff DF. How much does colonoscopy reduce colon cancer mortality? Ann Intern Med 2009, 150(1): 50-52.
26. Brenner H, Haug U, Arndt V et al. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology 2010; 138(3): 870-876.
27. Singh H, Turner D, Xue L et al. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 2006; 295(20): 2366-2373.
28. Brenner H, Chang-Claude J, Seiler CM et al. Does a negative screening colonoscopy ever need to be repeated? Gut 2006; 55(8): 1145-1150.
29. IARC Working Group on the Evaluation of Cancer-Preventive Strategies. Cervix Cancer Screening. Lyon: IARC-Press; 2005.
30. Hakama M, Räsänen-Virtanen U. Effect of a mass screening program on the risk of cervical cancer. Am J Epidemiol 1976; 103(5): 512-517.
31. Lǎǎrǎ E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1(8544): 1247-1249.
32. Nieminen P, Kallio M, Anttila A et al. Organised vs. spontaneous Pap-smear screening for cervical cancer: A case-control study Int J Cancer 1999; 83(1): 55-58.
33. Vainio H, Bianchini F. Breast Cancer Screening. Lyon: IARCPress 2002.
34. Karsa L, Anttila A, Ronco G et al. Cancer Screening in the European Union. Luxemburg: European Communities 2008.
35. Dušek L, Mužík J, Kubásek M et al. Epidemiology of Malignant Tumours in the Czech Republic 2007 [cited 2010 22 Sep]. Available from: http://www.svod.cz/.
36. Svobodník A, Daneš J, Skovajsová M et al. Current Results of the National Breast Cancer Screening Program in the Czech Republic. Klin Onkol 2007; 20 (Suppl 1): 161-165.
37. Perry N, Broeders M, de Wolf C et al. European guidelines for quality assurance in breast cancer screening and diagnosis. 4th ed. Luxembourg: Office for Official Publications of the EC 2006.
38. Frič P. The use of haemoccult test in the early diagnosis of colerectal cancer - experience from six pilot studies in Czechoslovakia. In: HardcastleJD (ed). Haemoccult screening for the early detection of colorectal cancer. Stuttgart. Schattauer 1986: 73-74.
39. Šachlová M, Novák J. Reflection about the Colorectal Carcinoma Screening Evolution. Klin Onkol 2009, 22(5): 242.
40. Zavoral M, Závada F, Frič P. Český národní program sekundární prevence kolorektálního karcinomu. Čes a Slov Gastroent a Hepatol 2005; 59(1): 7-10.
41. Zavoral M, Suchanek S, Zavada F et al Colorectal cancer screening in Europe. World J Gastroenterol 2009, 15(47): 5907-5915.
42. Lieberman D. A call to action - measuring the quality of colonoscopy. N Engl J Med 2006; 355(24): 2588-2589.
43. Rex DK. Quality in colonoscopy: cecal intubation first, then what? Am J Gastroenterol 2006; 101(4): 732-734.
44. Kaminski MF, Regula J, Kraszewska E et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362(19): 1795-1803.
45. Arbyn M, Anttila A, Jordan J et al. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Luxembourg: European Communities 2008.
46. Ferlay J, Shin H, Bray F et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, 2010 [cited 2010 22 Sep]. Available from: http://globocan.iarc.fr/.
47. Karim-Kos HE, de Vries E, Soerjomataram I et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44(10): 1345-1389.
48. Dušková J, Povýšil C, Juliš I et al National Cervical Cancer Screening Program from the Pathologists' point of view. Klin Onkol 2006; 19(1): 33-34
49. Sarkeala T, Anttila A, Forsman H et al. Process indicators from ten centres in the Finnish breast cancer screening programme from 1991 to 2000. Eur J Cancer 2004; 40(14): 2116-2125.
50. Lynge E, Olsen AH, Fracheboud J et al. Reporting of performance indicators of mammography screening in Europe Eur J Cancer Prev 2003; 12(3): 213-222.
51. Hofvind S, Geller B, Vacek PM et al. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol 2007; 22(7): 447-455.
52. Day NE, Williams DR, Khaw KT. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 1989, 59(6): 954-958.
53. Bennett RL, Blanks RG, Patnick J et al. Results from the UK NHS Breast Screening Programme 2000-2005. J Med Screen 2007; 14(4): 200-204.
54. Vejborg I, Olsen AH, Jensen MB et al. Early outcome of mammography screening in Copenhagen 1991-1999. J Med Screen 2002; 9(3): 115-119
55. Fracheboud J, Groenewoud JH, Boer R et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening. Int J Cancer 2006; 118(8): 2020-2025
56. U.S. Preventive Services Task Force. Screening for colorectal cancer. U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149(9): 627-637.
57. Federici A, Giorgi Rossi P, Borgia P et al. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes. a cluster randomized controlled trial. J Med Screen 2005; 12(2): 83-88.
58. Black ME, Yamada J, Mann V. A systematic literature review of the effectiveness of community-based strategies to increase cervical cancer screening. Can J Public Health 2002; 93(5): 386-393.
59. Cram P, Fendrick AM, Inadomi J et al. The impact of a celebrity promotional campaign on the use of colon cancer screening. the Katie Couric effect. Arch Intern Med 2003; 163(13): 1601-1605.